Fig. 2
IL-2 further repressed cell migration and proliferation in the presence of sorafenib. a–c An EdU assay was used to observe the proliferative cells. The number of EdU-positive cells was recorded. d–j Western blotting analysis for the proteins related to cell proliferation. IL-2 (5 ng/ml) treatment was carried out in the presence of 5 μM sorafenib. k–m A transwell assay was conducted to determine the cell migration in response to IL-2 and sorafenib co-treatment. n–r The proteins related to cell migration were analysed via western blotting. IL-2 (5 ng/ml) treatment was carried out in the presence of 5 μM sorafenib. *P < 0.05 vs. control group; #P < 0.05 vs. sorafenib group.Cont control